English

Ritonavir 155213-67-5

USP, GMP, Medical Grade

Contact Now

Product Detail

Product Information

Product name	Ritonavir
CAS No.	155213-67-5
Molecular Formula	C37H48N6O5S2
Molecular Weight	720.96
Quality Standard	99% up, USP42, Medicine Grade
Appearance	White powder

COA of Ritonavir

Items	Specifications	Results
Appearance	White to off-white powder	White powder
Solubility	Freely solution in methanol and in ethanol, soluble in 2-propanol	Conforms
Identification	HPLC: the retention time of the test sample corresponds to that of the reference standard IR: the infrared absorption spectrum of the test sample is concordant with the spectrum of reference standard	Conforms Conforms
Water content by KF	NMT 0.5%	0.06%
Specific optical rotation	+7.0°~+10.5°(c=2 in MeOH)	+10.21°
Residue on ignition	NMT 0.2%	0.10%
Heavy metals	NMT 20 ppm	Conforms
Sulphated ash	NMT 0.105	0.03%
Organic volatile impurities	Ethylacetate: NMT 0.5% Heptane: NMT 0.5% Tetrahydrofuran: NMT 0.072%	0.40% 0.16% ND
Related substances (by HPLC, area%)	Impurity E (RRT=0.36):NMT 0.3% ImpurityO(RRT=1.11):NMT 0.3% Impurity T (RRT=2.87):NMT 0.2% Any other individual impurity: NMT 0.1% Total impourities: NMT1.0%	0.08% ND ND Conforms 0.16%
Assay (by HPLC)	98.0%~102.0%	99.0%

Usage

Function of Ritonavir

What is Ritonavir ?

Ritonavir is a Whtie powder, It's CAS No. is 155213-67-5, It's molecular formula is C37H48N6O5S2.
Ritonavir, with trade name Norvir (AbbVie, Inc.), is an antiretroviral drug from the protease inhibitor class used to treat HIV infection and AIDS.

Function of Ritonavir

Ritonavir is an HIV protease inhibitor that interferes with the reproductive cycle of HIV.
It is now more commonly used as a booster of other protease inhibitors and is available in both liquid formulation and as capsules.

Application of Ritonavir

1. Ritonavir is an antiretroviral drug from the protease inhibitor class used to treat HIV infection and AIDS.

2. Ritonavir is a Pharmaceutical raw materials.
3. Although it was initially developed as an independent agent, it has been shown to possess advantageous properties in combination regimens with low-dose ritonavir and other protease inhibitors.